PeptideStack
5.2kquestions
20kanswers
220users

Why did two BCH lots of cagrilintide differ on content assay?

Asked 16 Sept 2024Modified 21 months agoViewed 42k times
38

Stated plainly: BCH · cagrilintide.

I noticed this today and I have not touched anything since, in case the state is diagnostic.

I have not discarded anything yet, so a test is still possible if that is the recommendation.

How do I distinguish the benign explanation from the one that matters?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questionscontent-assay
content-assay

Quantified content: how many milligrams of peptide are actually in the vial, measured against a calibrated reference standard. A separate test…

438 questionsvendor-vetting
vendor-vetting

Evaluating a supplier on evidence rather than reputation: testing history across batches, whether certificates are batch-specific, how failures…

436 questions
shareeditfollowflag
DH
askedDr_Jonas_Halvorsen41k3816 Sept 2024
2This should probably be in the site help pages rather than buried in an answer. – tobias_reint 5 months ago
3Good answer, but the confidence interval in the cited trial is wider than implied. – Dr_Aoife_Brennan 6 months ago
add a comment

3 Answers

Accepted answer first, then by votes
77

Accepted answer

The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

It helps to be literal here: the sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

If testing multiple vials, state how many you tested and why you chose those vials.

shareimprove this answerflag
P9
answered · acceptedplate_count_9k95k15813 Oct 2024
5Useful. I have added the accept threshold suggestion to my own notes. – n_takahashi 5 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
70

Thermal history during shipping is different for every vial, so a lot that experienced thermal abuse may have internal variation even if it was originally homogeneous.

The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

The part that matters: testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.

The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.

Assume segregation is possible, and design your sampling to catch it if it exists.

shareimprove this answerflag
DL
answeredDr_Otto_Lindqvist38k382 Oct 2024
6Have you seen anything published on this, or is it inference from the mechanism? – rhian_prydderch 10 months ago
5Useful. I have added the accept threshold suggestion to my own notes. – fresh_bac 8 months ago
add a comment
37

A certificate that reports one test result on one vial extrapolates to claim that all two hundred vials in the lot are identical, which is an assumption worth questioning.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

edited 25 Oct 2024 by ines_brandt — added the method parameters

shareimprove this answerflag
IB
answeredines_brandt93k24825 Oct 2024

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.